Benzinga | Feb 22, 2021 09:02AM EST

AIkido Pharma Provides Update On Antiviral Platform; Says New Compounds Being Tested Against Influenza With SARS-CoV-2 Testing In The Future

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced an update on its broad spectrum anti-viral platform compounds with the potential to treat influenza, COVID-19, Ebola and other viral infections. The initial two lead compounds, which target the SKI complex in humans, have been optimized through the use of computer assisted learning, through two rounds of chemical modifications to achieve drug-like properties required to move the compounds into animal testing. In addition, a third lead compound has been identified and will be subjected to optimization. These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future. Subsequently, the top analogs from each series of lead compounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.

Anthony Hayes, CEO of AIkido Pharma, stated, "We are excited to be using Artificial Intelligence technology to advance the development of these compounds and proud to announce these advancements in the research."